Deutsche Bank AG Takes $2.04 Million Position in Sarepta Therapeutics, Inc. $SRPT

Key Points

• Deutsche Bank acquired 113,724 Sarepta Therapeutics shares worth approximately $2.04 million during the second quarter, representing about 0.11% of the company.
• Institutional investors own 86.68% of Sarepta, with major funds including AQR Capital Management, First Trust Advisors, Vanguard, Bank of New York Mellon and Amundi increasing or initiating positions.
• Analyst sentiment is mixed: Sarepta has a consensus “Hold” rating and an average price target of $25.06. The company beat quarterly EPS and revenue estimates, but revenue declined 34.3% year over year.

Deutsche Bank AG acquired a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 113,724 shares of the biotechnology company's stock, valued at approximately $2,044,000. Deutsche Bank AG owned about 0.11% of Sarepta Therapeutics at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. AQR Capital Management LLC grew its position in Sarepta Therapeutics by 454.6% in the 4th quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company's stock worth $167,781,000 after purchasing an additional 6,390,860 shares during the last quarter. First Trust Advisors LP raised its position in shares of Sarepta Therapeutics by 107.6% during the first quarter. First Trust Advisors LP now owns 4,135,788 shares of the biotechnology company's stock valued at $89,995,000 after buying an additional 2,143,211 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Sarepta Therapeutics by 9.2% during the fourth quarter. Vanguard Group Inc. now owns 11,810,729 shares of the biotechnology company's stock valued at $254,167,000 after buying an additional 993,283 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Sarepta Therapeutics in the second quarter valued at about $13,912,000. Finally, Amundi lifted its stake in shares of Sarepta Therapeutics by 378.2% in the third quarter. Amundi now owns 969,826 shares of the biotechnology company's stock valued at $18,689,000 after buying an additional 767,026 shares during the period. Institutional investors own 86.68% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on SRPT shares. Piper Sandler reduced their price objective on Sarepta Therapeutics from $23.00 to $20.00 and set a "neutral" rating for the company in a research report on Thursday, July 9th. Zacks Research upgraded Sarepta Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 12th. Wolfe Research upgraded Sarepta Therapeutics from a "peer perform" rating to an "outperform" rating and set a $27.00 target price for the company in a research note on Thursday, July 9th. HC Wainwright reaffirmed a "buy" rating on shares of Sarepta Therapeutics in a research report on Tuesday, July 28th. Finally, Wall Street Zen downgraded shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Nine investment analysts have rated the stock with a Buy rating, six have given a Hold rating and five have assigned a Sell rating to the company. According to data from MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of "Hold" and an average price target of $25.06.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $20.86 on Friday. The stock has a market capitalization of $2.20 billion, a P/E ratio of -7.19, a price-to-earnings-growth ratio of 0.32 and a beta of 0.23. The company has a current ratio of 4.42, a quick ratio of 2.62 and a debt-to-equity ratio of 0.55. Sarepta Therapeutics, Inc. has a 1 year low of $14.68 and a 1 year high of $25.32. The firm has a 50 day moving average of $17.73 and a 200-day moving average of $18.32.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 EPS for the quarter, topping analysts' consensus estimates of $0.22 by $0.42. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%.The business had revenue of $401.25 million for the quarter, compared to analyst estimates of $366.39 million. During the same period in the prior year, the company earned $2.02 EPS. Sarepta Therapeutics's revenue for the quarter was down 34.3% on a year-over-year basis. As a group, sell-side analysts anticipate that Sarepta Therapeutics, Inc. will post 3.43 EPS for the current fiscal year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta's core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company's mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta's commercial products include several exon-skipping therapies approved by the U.S.

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source